Boston Scientific has announced the schedule of key data presentations, including two late-breaking clinical trials that will be featured at the Heart Rhythm Society’s 38th Annual Scientific Sessions (10‒12 May, Chicago, USA).
Notably, the post-market approval data collected on the Subcutaneous Implantable Defibrillator (S-ICD) System in the US, as well as real-world data regarding the efficacy of the Watchman Left Atrial Appendage Closure (LAAC) Device, will be presented during late-breaking clinical trial sessions on 11 and 12 of May, respectively. Other scheduled presentations and abstracts underscore the following:
- extended follow-up on pacing performance with the Acuity X4 Quadripolar Left Ventricular leads;
- additional pre-clinical evidence supporting the company’s modular therapy approach and communications compatibility between its Empower Modular Pacing System and the Emblem MRI Subcutaneous Implantable Defibrillator (S-ICD) System;
- pre-clinical data showcasing new software that further expands the diagnostic capabilities of the Rhythmia HDx Mapping System.
“We are pleased to present growing evidence that reinforces the safety and efficacy of technologies across our cardiovascular portfolio,” says Kenneth Stein, senior vice president and chief medical officer, Rhythm Management and Global Health Policy, Boston Scientific. “Further, we look forward to results gathered by independent research within the clinical community that embrace our cardiac mapping technology and evaluate the performance of its differentiating features.”
Abstracts of interest (listed chronologically)
Thursday, 11 May
- Late-Breaking Clinical Trial: The S-ICD Post-Market Approval Study: Michael R Gold, will present at 8:00 in room 375E.
- Evaluation of an Automatic Screening Tool for S-ICD Patient Selection: A poster authored by Venugopal Allavatam will be available for viewing from 9:30‒12:00 in Epicenter, Exhibit Hall.
Cardiac resynchronisation therapy defibrillator (CRT-D) and implantable cardioverter defibrillator (ICD)
- Right ventricular lead location, right-left ventricular lead interaction, and long-term mortality in cardiac resynchronization therapy patients: Usama Daimee will present at 14:30 in room 186.
- Multiple procedures increase the risk of infection but not mechanical complications in patients with implantable cardiac defibrillators: Jayanthi N Koneru will present at 14:45 in Room 375D.
Friday, 12 May
Watchman LAAC Device
- Late-Breaking Clinical Trial: EWOLUTION Trial: 1-Year efficacy and safety of left atrial appendage closure with Watchman in patients with or without contraindication to oral anticoagulation: Lucas V A Boersma will present at 11:00 in Room 375E.
- Chronic performance of communicating leadless anti-tachycardia pacemaker and subcutaneous implantable cardioverter defibrillator: Fleur VY Tjong will present at 13:30 in Room 375D.
- Propensity score matched comparsion of Subcutaneous and Transvenous Implantable Defibrillator Therapy in the SIMPLE and EFFORTLESS studies: A poster authored by Tom F Brouwer and Jeffrey S Healey will be available for viewing from 14:00–17:00 in Epicenter, Exhibit Hall.
CRT-D and ICD
- Extended follow-up of a family of anatomically designed quadripolar left ventricular leads: A poster authored by Suneet Mittal will be available for viewing from 14:00–17:00 in Epicenter, Exhibit Hall.
- Local Impedance via mini electrodes successfully measures catheter-tissue contact and is strongly correlated to radiofrequency lesion dimensions in explanted swine hearts: A poster authored by Matthew S Sulkin will be available for viewing from 14:00–17:00 in Epicenter, Exhibit Hall.
- Local impedance via mini electrodes as an in vivo indicator of catheter-tissue coupling and lesion maturation: Jacob I Laughner will present at 15:15 in Epicenter, Exhibit Hall.
All presentations are listed in Central Time and will take place at McCormick Place West Convention Center.